Literature DB >> 12739030

Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1.

M C Blatter-Garin, B Kalix, S De Pree, R W James.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12739030     DOI： 10.1007/s00125-003-1065-0

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  8 in total

Review 1.  Aspirin.

Authors:  E H Awtry; J Loscalzo
Journal:  Circulation       Date:  2000-03-14       Impact factor: 29.690

2.  LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in healthy subjects.

Authors:  Michelangela Barbieri; Massimiliano Bonafè; Raffaele Marfella; Emilia Ragno; Dario Giugliano; Claudio Franceschi; Giuseppe Paolisso
Journal:  J Clin Endocrinol Metab       Date:  2002-01       Impact factor: 5.958

3.  The hunt for nutritional and pharmacological modulators of paraoxonase.

Authors:  P N Durrington; B Mackness; M I Mackness
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-08-01       Impact factor: 8.311

4.  Paraoxonase-1 L55M polymorphism is associated with an abnormal oral glucose tolerance test and differentiates high risk coronary disease families.

Authors:  Sara Deakin; Ilia Leviev; Viviane Nicaud; Marie-Claude Brulhart Meynet; Laurence Tiret; Richard W James
Journal:  J Clin Endocrinol Metab       Date:  2002-03       Impact factor: 5.958

5.  Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation.

Authors:  M Boemi; I Leviev; C Sirolla; C Pieri; M Marra; R W James
Journal:  Atherosclerosis       Date:  2001-03       Impact factor: 5.162

Review 6.  Paraoxonase and coronary heart disease.

Authors:  M I Mackness; B Mackness; P N Durrington; A M Fogelman; J Berliner; A J Lusis; M Navab; D Shih; G C Fonarow
Journal:  Curr Opin Lipidol       Date:  1998-08       Impact factor: 4.776

7.  Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease.

Authors:  R W James; I Leviev; A Righetti
Journal:  Circulation       Date:  2000-05-16       Impact factor: 29.690

8.  Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins.

Authors:  C A Abbott; M I Mackness; S Kumar; A J Boulton; P N Durrington
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-11       Impact factor: 8.311
  8 in total
  13 in total

Review 1.  Paraoxonase 1, atherosclerosis and arterial stiffness in renal patients.

Authors:  Ozkan Gungor; Fatih Kircelli; Huseyin Toz
Journal:  Int Urol Nephrol       Date:  2012-06-06       Impact factor: 2.370

Review 2.  Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.

Authors:  Daniel Seung Kim; Judit Marsillach; Clement E Furlong; Gail P Jarvik
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

Review 3.  Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on.

Authors:  Lucio G Costa; Gennaro Giordano; Clement E Furlong
Journal:  Biochem Pharmacol       Date:  2010-11-18       Impact factor: 5.858

Review 4.  The human paraoxonase gene cluster as a target in the treatment of atherosclerosis.

Authors:  Zhi-Gang She; Hou-Zao Chen; Yunfei Yan; Hongliang Li; De-Pei Liu
Journal:  Antioxid Redox Signal       Date:  2011-10-18       Impact factor: 8.401

5.  Impact of antibacterial drugs on human serum paraoxonase-1 (hPON1) activity: an in vitro study.

Authors:  Hakan Söyüt; Elif Duygu Kaya; Sükrü Beydemir
Journal:  Asian Pac J Trop Biomed       Date:  2014-08

6.  Effects of PON1 Gene Promoter DNA Methylation and Genetic Variations on the Clinical Outcomes of Dual Antiplatelet Therapy for Patients Undergoing Percutaneous Coronary Intervention.

Authors:  He-Ping Lei; Xi-Yong Yu; Hong Wu; Yan-Hong Kang; Wan-Ping Zhong; Li-Yun Cai; Meng-Zhen Zhang; Ji-Yan Chen; Li-Ping Mai; Qing-Shan Ding; Min Yang; Shi-Long Zhong
Journal:  Clin Pharmacokinet       Date:  2018-07       Impact factor: 6.447

Review 7.  Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis.

Authors:  Emanuele D'Amico; Pam Factor-Litvak; Regina M Santella; Hiroshi Mitsumoto
Journal:  Free Radic Biol Med       Date:  2013-06-21       Impact factor: 7.376

8.  Abnormal paraoxonase-1 (PON1) enzyme activity in idiopathic inflammatory myopathies.

Authors:  Sangmee Sharon Bae; Ani Shahbazian; Jennifer Wang; Ilana Golub; Buzand Oganesian; Tyler Dowd; Beata Vayngortin; Ryan Wang; David Elashoff; Srinivasa T Reddy; Christina Charles-Schoeman
Journal:  Rheumatology (Oxford)       Date:  2022-05-30       Impact factor: 7.046

9.  Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin.

Authors:  Priscilla Jaichander; Krithika Selvarajan; Mahdi Garelnabi; Sampath Parthasarathy
Journal:  J Lipid Res       Date:  2008-06-02       Impact factor: 5.922

10.  Implications of serum paraoxonase activity in obesity, diabetes mellitus, and dyslipidemia.

Authors:  Sunil K Kota; Lalit K Meher; Siva K Kota; Sruti Jammula; S V S Krishna; Kirtikumar D Modi
Journal:  Indian J Endocrinol Metab       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.